| Author (Corporate) | European Commission: Press and Communication Service |
|---|---|
| Series Title | Press Release |
| Series Details | IP/05/1354 (27.10.05) |
| Publication Date | 27/10/2005 |
| Content Type | News |
|
Supported by the EU Research Framework Programme, influenza experts from the UK, Italy and Norway, working with vaccine researchers from Sanofi Pasteur in France, developed the first human candidate vaccine for the H7N1 virus. Following this research breakthrough, it was planned that this new vaccine, called ‘RD-3’, would go into clinical trials in Spring 2006. Most vaccine development had centred on H5N1 thus far, the highly pathogenic form of the avian influenza ('bird flu'). |
|
| Source Link | Link to Main Source http://europa.eu/rapid/pressReleasesAction.do?reference=IP/05/1354&format=HTML&aged=0&language=EN&guiLanguage=en |
| Related Links |
|
| Subject Categories | Business and Industry, Health |
| Countries / Regions | Europe |